The stock is down on a predictable, already-announced Entresto patent cliff (Entresto -42% YoY in Q1) and the market is ...

The global pancreatic neuroendocrine tumors (PNETs) market is experiencing significant growth driven by rising incidence rates, advances in diagnostic imaging, and expanding therapeutic options. PNETs ...

Questions about Covid vaccine safety, media reporting, and access to clinical trial data have resurfaced following criticism ...

Relay Therapeutics (NASDAQ:RLAY) outlined new data and development plans for its lead oncology program, zovegalisib, during a “frontline breast cancer update” conference call, highlighting encouraging ...

Pfizer Inc. (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the ...

Lyme disease is the most common tick-borne infectious disease in the United States. Named for the Connecticut town where it was first reported in the 1970s, Lyme is prevalent in the northeast and ...

The firm is planning to begin a Phase III study evaluating zovegalisib, atirmociclib, and an aromatase inhibitor in early 2027.

With Xtandi's growth days numbered, an unfazed Astellas expects a group of new products will more than offset the decline of ...

As Pfizer gears up to defend its patents on transthyretin amyloid cardiomyopathy (ATTR-CM) med tafamidis in court this week, ...

Wages cover the bills. Dividends buy back your time. Earned income stops when you do; portfolio income deposits into your ...

Researchers conducted a retrospective cross-sectional analysis of patients diagnosed with de novo metastatic breast cancer to evaluate presentation and treatment differences across three main subtypes ...

On March 23, Pfizer issued a press release announcing that a new Lyme disease vaccine candidate has demonstrated “strong ...